Stem stock forecast upside remains credible due to

Stem stock forecast upside remains credible due to upcoming medical conference announcements, likely to boost sentiment and spark price momentum. Cannabis stocks have been on an absolute tear in the past month as investors are optimistic that marijuana will soon be legalized at the federal level in the U.S. Curaleaf (CURLF) stock has surged nearly 90% year-to-date, making it the top performer among pot stocks tracked by Barchart . A key highlight of the first-quarter 2025 results was the continued expansion in STEM’s recurring revenue streams. Annual recurring revenue (ARR) reached $57 million, up 8% year over year, whereas contracted annual recurring revenue (CARR) grew 7% sequentially to $69 million. These metrics underscore the strength and scalability of STEM’s software and services portfolio, which is increasingly contributing to long-term revenue visibility and improved profitability. Operational metrics showed meaningful improvement. Solar operating AUM reached 32.4 GW, representing a 20% year-over-year increase and an 8% sequential gain. Storage Operating AUM doubled to 1.6 GWh from the same period last year. However, bookings in the reported quarter came in at $34.5 million, slightly below the $37.6 million reported in the year-ago quarter. STEM’s contracted backlog rose 21% sequentially to $25.3 million, reflecting solid underlying demand and a healthy project pipeline moving forward. Macroeconomic data reinforces stem stock forecast optimism as inflation cools, freeing up more capital for high-growth biotech equities.